resistance, page-34

BTA cracks a mention on FOX news, in reference to WHO announcement;

http://www.foxnews.com/story/0,2933,579030,00.html

"Zanamivir should be considered as the treatment of choice for patients who develop prolonged influenza illness despite treatment with oseltamivir," it said.

GlaxoSmithKline and Biota make zanamivir under the brand name of Relenza, a flu drug that must be inhaled.

"Once oseltamivir resistant virus has been detected in a ward treating severely immuno-compromized patients, doctors should consider switching to zanamivir as the antiviral drug of first choice for treatment," the WHO said.

Zanamivir should also be considered for preventive treatment of other patients on the ward who have been exposed, it added.